PATENT ASSIGNMENT AGREEMENT THIS PATENT ASSIGNMENT AGREEMENT ("Agreement") is entered as of the 1st day of May 2006 ("EFFECTIVE DATE") by and between WORLD WASTE TECHNOLOGIES, with offices at 13520 Evening Creek Drive North, Suite 130, San Diego, CA...Patent Assignment Agreement • May 5th, 2006 • World Waste Technologies Inc • Refuse systems
Patent Assignment AgreementPatent Assignment Agreement • May 2nd, 2024 • Delaware
This Patent Assignment Agreement (this “Agreement”) is made as of , 2024 (the “Effective Date”), by and between , a [corporation/individual] with an address at (“Assignor”), and IP3 2024, Series 924 of Allied Security Trust I, a series of a Delaware statutory trust with an address at 100 Overlook Center, 2nd Floor, Princeton, New Jersey 08540, U.S.A. (“Assignee”) (hereinafter referred to collectively as the “Parties” and individually as a “Party”).
ContractPatent Assignment Agreement • May 5th, 2020 • Washington
EX-10.47 11 v52057a5exv10w47.htm EX-10.47 Exhibit 10.47 PATENT ASSIGNMENT AGREEMENT This agreement (the “Agreement”) is made effective the 23rd day of February 2009 (the “Effective Date”) between Omeros Corporation, a Washington corporation having a principal place of business at 1420 Fifth Avenue, Suite 2600, Seattle WA 98101 USA (“Omeros”) and Roberto Ciccocioppo, Ph.D., having a residence at Vicolo San Silvestro n. 25, Camerino, 62032 IT (“Dr. Ciccocioppo”). WHEREAS Dr. Ciccocioppo owns all rights to certain technology invented by Dr. Ciccocioppo related to new uses of peroxisome proliferator-activated receptor gamma (“PPARg”) agonists; and WHEREAS Omeros has provided services for and funded the expenses of filing patent applications for Dr. Ciccocioppo’ PPARg technology; and WHEREAS Omeros wishes to acquire all rights to Dr. Ciccocioppo’ PPARg technology and related patent applications and patents; and WHEREAS Dr. Ciccocioppo wishes to sell all rights to his PPARg technology to Ome
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • September 5th, 2014 • Endostim, Inc. • Electromedical & electrotherapeutic apparatus • Missouri
This Patent Assignment Agreement (“Agreement”) is entered into as of September 2, 2009 (“Effective Date”) by and among VIRENDER SHARMA, M.D. (“Dr. Sharma”) and SARAH M. SHARMA (“Sarah Sharma”), husband and wife and both of whom being Arizona residents (together “Assignor”), ENDOSTIM, INC., a Delaware corporation (“Assignee”), and ENDOSTIM, INC., an Arizona corporation (“EndoStim Arizona”). EndoStim Arizona is a party to this Agreement only for the purpose set forth in Section 3.3 of this Agreement.
Patent Assignment AgreementPatent Assignment Agreement • March 9th, 2022
THIS AGREEMENT is made this day of , 20 , by and between (the “Assignor”), having its primary place of business at _________ , and __________ ___ (the “Assignee”) having its primary place of business at (collectively the “Parties”).
EX-10.1 2 d374286dex101.htm PATENT ASSIGNMENT AGREEMENT 20120626 – EXECUTION COPY Agreement Reference Number L126670Patent Assignment Agreement • May 5th, 2020 • New York
PATENT ASSIGNMENT AGREEMENT (“Agreement”) with an Effective Time & Date as defined below, between INTERNATIONAL BUSINESS MACHINES CORPORATION, a New York corporation (“IBM”), and ULTRATECH (“BUYER”), a Delaware corporation.
EX-10.19 4 dex1019.htm PATENT ASSIGNMENT AGREEMENT EXECUTION COPY PATENT ASSIGNMENT AGREEMENT BY AND BETWEEN LENOVO (BEIJING) LIMITED, AND LEGEND HOLDINGS LIMITED YU BING WANG ZHENG for and on behalf of LWY Agreement Reference NumberPatent Assignment Agreement • May 5th, 2020
This PATENT ASSIGNMENT AGREEMENT, dated as of October 19, 2004, is entered into by and between Lenovo (Beijing) Limited, a company established under the laws of the People’s Republic of China (“Assignor”), and Legend Holdings Limited, Yu Bing and Wang Zheng, for and on behalf of LWY (as defined below) (“Assignee”). Assignor on the one hand, and Assignee on the other hand, are each sometimes referred to herein as a “Party” and collectively as the “Parties” to this Agreement.
ARCA biopharma Announces rNAPc2 COVID-19 Patent Assignment AgreementPatent Assignment Agreement • July 7th, 2021 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
• Provides exclusive world-wide patent rights to the use of rNAPc2 as a potential treatment for COVID‑19 and other indications
PATENT ASSIGNEMENT CONSIDERATION AGREEMENTPatent Assignment Agreement • June 30th, 2015 • Zynerba Pharmeceuticals, Inc. • Pharmaceutical preparations • Delaware
This Patent Assignment Consideration Agreement (this “Agreement”) is made and entered into this 21st day of August, 2014 (the “Effective Date”), by and between Albany College of Pharmacy, a university located at 106 New Scotland Road, Albany, NY 12208-3492 (“Assignor”), and Zynerba Pharmaceuticals, Inc. (f/k/a AllTranz, Inc.), a Delaware corporation located at 1122 Oak Hill Drive, Lexington, KY 40505 (“Assignee”).
AMENDMENT NO. 1 TO PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • September 5th, 2014 • Endostim, Inc. • Electromedical & electrotherapeutic apparatus • Missouri
THIS AMENDMENT NO. 1 TO PATENT ASSIGNMENT AGREEMENT (this “Amendment”) is made and entered into this 11th day of January, 2010 (the “Effective Date”), by and among VIRENDER SHARMA, M.D. (“Dr. Sharma”) and SARAH M. SHARMA (“Sarah Sharma”), husband and wife and both of whom being Arizona residents (together “Assignor”), ENDOSTIM, INC., a Delaware corporation (“Assignee”) and ENDOSTIM, INC., an Arizona corporation (“EndoStim Arizona”). EndoStim Arizona is only a party to this Amendment to confirm that it has no ownership or other interest, however defined or classified, in any Intellectual Property or Patent Assets.
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • September 22nd, 2022 • Cadrenal Therapeutics, Inc. • Pharmaceutical preparations
THIS PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is dated as of April 1 , 2022 (“Effective Date”), and is made by and between HESP LLC, a Delaware limited liability company (“Assignor”), and Cadrenal Therapeutics Inc., a Delaware corporation (“Assignee”). Each of Assignor and Assignee may be referenced herein as a “Party,” and collectively, the “Parties.”
Patent Assignment AgreementPatent Assignment Agreement • June 23rd, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations
This Patent Assignment Agreement (this “Agreement”), effective as of October 25, 2019, is signed by and between Sagimet Biosciences Inc. (formerly known as 3-V Biosciences, Inc.), a corporation organized under the laws of Delaware, having a principal place of business at 155 Bovet Road Suite 303, San Mateo, CA 94402 (hereinafter referred as “Assignor” or “Sagimet”); and Gannex Pharma Co., Ltd. ( 甘莱制药有限公司), an affiliate of Ascletis BioScience Co., Ltd. (both wholly-owned subsidiaries of Ascletis Pharma Inc.) and a corporation under the laws of China having a registered office at No. 665 Zhangjiang Road, 3rd Floor, Shanghai Pilot Free Trade Zone, Shanghai, China (hereinafter referred to as "Assignee").
English Translation of Patent Assignment AgreementPatent Assignment Agreement • March 27th, 2009 • Asian Financial Inc • Printing trades machinery & equipment
Whereas, the Assignor (Beijing Huiyuan Duoyuan Digital Technology Institute) owns the patent for a device for automatic, quick clearing of printing press ink system with the following details: its patent number being 00254747.3, its publication number being Hao CN 2447175, its application date being September 25, 2000, and its duration being 10 years;
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • November 29th, 2020
This Patent Assignment Agreement (this “Agreement”) is entered into this ______ day of ______, 20__ (the “Effective Date”) by and between Hiroshima University, a national university corporation organized under the laws of Japan, with its principal address at 1-3-2 Kagamiyama, Higashi-Hiroshima City, Japan 739-8511 (the “University”) and __________, a company organized under the laws of ___________________, with its principal address at ___________________ (the “Assignee”).
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • December 29th, 2014 • Flex Pharma, Inc. • Pharmaceutical preparations
This PATENT ASSIGNMENT AGREEMENT is dated as of March 20, 2014 (this “Assignment”), by RODERICK MACKINNON, DONALD MACKINNON, and BRUCE BEAN, individuals residing at 504 East 63rd Street, Apt 33M, New York, NY 10065, 305 East 85th St. Apt 17A, New York, NY 10028, and 20 Locke Road, Waban, MA 02468 respectively (collectively “Assignors”), and FLEX PHARMA, INC., with offices at Prudential Tower, 800 Boylston Street, c/o Longwood Fund, Boston, MA 02199 (“Assignee”).
Amended and Restated Patent Assignment AgreementPatent Assignment Agreement • July 10th, 2023 • Sagimet Biosciences Inc. • Pharmaceutical preparations
This Amended and Restated Patent Assignment Agreement (this “Agreement”), effective as of October 25, 2019, is signed by and between Sagimet Biosciences Inc. (formerly known as 3-V Biosciences, Inc.), a corporation organized under the laws of Delaware, having a principal place of business at 155 Bovet Road, Suite 303, San Mateo, CA 94402 (hereinafter referred as "Assignor''); and Gannex Pharma Co., Ltd (甘莱制药有限公司), a corporation under the laws of China having a registered office at No. 665 Zhangjiang Road, 3rd Floor, Shanghai Pilot Free Trade Zone, Shanghai, China (hereinafter referred to as “Assignee”). Assignee is an affiliate of Ascletis BioScience Co. Ltd. (also known as 歌礼生物科技（杭州）有限公司) (“Ascletis”), and both Assignee and Ascletis are wholly-owned subsidiaries of Ascletis Pharma Inc.
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • May 11th, 2015 • Concert Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This PATENT ASSIGNMENT AGREEMENT (this “Agreement”) is entered into as of September 8, 2011 (the “Effective Date”) by and between AUSPEX PHARMACEUTICALS, INC., a Delaware corporation with its registered office at 3366 North Torrey Pines Court, Suite 225, La Jolla, California, 92037 (“Auspex”), and CONCERT PHARMACEUTICALS, INC., a Delaware corporation, with its registered office at 99 Hayden Avenue, Suite 500, Lexington, MA 02421 (“Concert”). Auspex and Concert are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
RECITALSPatent Assignment Agreement • April 1st, 2002 • Frisby Technologies Inc • Plastics foam products • North Carolina
Patent Assignment Agreement (English Translation)Patent Assignment Agreement • July 14th, 2011 • Tongli Pharmaceuticals (USA), Inc. • Pharmaceutical preparations
AGREEMENTPatent Assignment Agreement • May 10th, 2010 • Virtual Closet, Inc. • Household audio & video equipment
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • September 12th, 2018 • Marizyme Inc • Wholesale-furniture & home furnishings
THIS PATENT PURCHASE AND ASSIGNMENT AGREEMENT (the “Agreement”) is dated as of September 12th, 2018, by and between ACB Holding AB, Reg. No. 559119-5762 a Sweden company, with an address at Kraftriket 11B, 114 19 Stockholm, Sweden (“Assignor”) and Marizyme, Inc., a Nevada corporation formerly known as GBS Enterprises Incorporated, with an address at 2295 Towne Lake Parkway Suite 116-290 Woodstock, GA 30189 (the “Assignee”).
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • November 9th, 2011 • Unigene Laboratories Inc • Medicinal chemicals & botanical products • New Jersey
THIS PATENT ASSIGNMENT AGREEMENT (the “Agreement”) is made and is effective as of September 15, 2011 (the “Effective Date”), by and between UNIGENE LABORATORIES, INC., a Delaware corporation having a place of business at 110 Little Falls Road, Fairfield, NJ 07004 (hereinafter referred to as “Company”) and KIERAN MURPHY, LLC, having its office at 100 West Road, Suite 300, Towson, MD 21210 (hereinafter referred to as “Murphy”).
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • March 8th, 2017 • Vivus Inc • Pharmaceutical preparations • California
This Patent Assignment Agreement is entered into as of the Effective Date (as defined below), by and between Selten Pharma, Inc., a Cayman Islands company, having a principal place of business at 751 Laurel St, #520, San Carlos, CA 94070, (“SELTEN”) and VIVUS, Inc., a Delaware company having a principal place of business at 900 E. Hamilton Ave., Suite 550, Campbell, California 95008 (“VIVUS”).
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • August 9th, 2005 • Orthologic Corp • Pharmaceutical preparations • Texas
This Patent Assignment Agreement (this “Assignment Agreement”), effective the 28th day of June, 2005 (the “Effective Date”), is by and between the Board of Regents (“Board” or “Assignor”) of The University of Texas System, an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701 (“System”), through its component institution, The University of Texas Medical Branch at Galveston, having a business address at 301 University Blvd., Galveston, Texas 77555 (“University”) and OrthoLogic Corp., a Delaware corporation, having a principal place of business located at 1275 West Washington Street, Tempe, AZ 85281 (“OLGC” or “Assignee”).
INTEGRATED SECURITY TECHNOLOGIES, INC. Vancouver, B.C. V6C 3E8Patent Assignment Agreement • February 17th, 2006 • Integrated Security Technologies, Inc. • Mining & quarrying of nonmetallic minerals (no fuels) • British Columbia
This letter sets out the agreement (“Agreement”) reached among Integrated Security Technologies, Inc. as purchaser (“IST”) and Hadasit Medical Research Services and Development Ltd. (“Hadasit”) regarding the transfer and sale by Hadasit of patent and patent applications as detailed in Exhibit A hereto and other related state patents and patent applications, including all of the related know-how and technology related to the administering of insulin orally as a method to replace insulin injections (collectively, the “Patent”) to IST, upon the terms and conditions set forth herein.
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • September 20th, 2005 • Stinger Systems, Inc • Ordnance & accessories, (no vehicles/guided missiles)
Dated: [Date]Patent Assignment Agreement • October 23rd, 2014
ContractPatent Assignment Agreement • January 7th, 2024
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • July 22nd, 2016 • Accurexa Inc. • Electromedical & electrotherapeutic apparatus • Delaware
AGREEMENTPatent Assignment Agreement • February 16th, 2007 • Champions Sports Inc • Retail-eating & drinking places
THIS AGREEMENT, executed in quintuplicate, is by and among Saeed R. Khan, residing in Owings Mills, Maryland (hereinafter “Khan”), Gurulingappa Hallur, residing in Owings Mills, Maryland (hereinafter “Hallur”), Manuel Hidalgo, residing in Baltimore, Maryland (hereinafter “Hidalgo”), Antonio Jimeno, residing in Baltimore, Maryland (hereinafter “Jimeno”) and Champions Biotechnology, Inc., a Delaware corporation, located at 2200 Wilson Boulevard, Suite 102-316, Arlington, Virginia 22201 (hereinafter “Champions”);
PATENT ASSIGNMENT AGREEMENTPatent Assignment Agreement • November 5th, 2014 • Vivus Inc • Pharmaceutical preparations • New York
This Patent Assignment Agreement is entered into as of the Execution Date (as defined below), by and between Janssen Pharmaceuticals, Inc., a Pennsylvania company having a principal place of business at 1125 Trenton-Harbourton Road, Titusville, New Jersey 08560 (“JANSSEN”) and VIVUS, Inc., a Delaware company having a principal place of business at 351 E. Evelyn Ave., Mountain View, California 94041 (“VIVUS”).
Contract ReviewPatent Assignment Agreement • July 17th, 2003
UW Patent Assignment Agreement (PAA)Patent Assignment Agreement • February 13th, 2018
The Faculty Senate's Special Committee on Intellectual Property and Commercialization (SCIPC) and the President's Intellectual Property Management Advisory Committee (IPMAC) have recommended improvements to the process of requesting and receiving prior approval for outside work for compensation. The resulting recommendations were accepted and incorporated into the Form 1460 by the Office of Research, which has the responsibility and authority for administering the Outside Professional Work process for Faculty, Librarians, and Academic Staff on behalf of the Provost.
Patent assignment agreement templatePatent Assignment Agreement • March 10th, 2021
This patent task (hereinafter assignment) is made and entered by and between [Date of Insertion] (effective date): [Name of assignor] [Add assignor address] (assignor) AND [Add assignee name] [Add assignee address] (assignee) (assignee) CONSIDERING that the determinant is the sole and lawful owner of certain ideas, inventions, their patent applications and patents (hereinafter collectively, patents) submitted in the exhibition annexed to this document; Whereas the investor wishes to purchase or acquire the acquirer's right, ownership and interest in and in patents; WHEREAS the assignor and the investor are both duly authorised and able to enter into this task. Thus, for a valuable fee, the receipt of which is confirmed, the parties agree on the following: TASK 1. The assignor hereby sells, determines, transfers and transfers to the acquirer [Amount of Annex]% of his right, ownership and interest in patents granted to the assignee for the entire duration and re-issue or renewal of paten
Patent assignment agreement pdfPatent Assignment Agreement • October 24th, 2020
having WHEREAS the assignor is the proprietor of all rights, property rights and interests in patents and patent applications and the originator of inventions (hereinafter collectively referred to as 'patent rights') on the attached list. WHEREAS the Transferee wishes to obtain all rights, ownership and interests in inventions granted by patent rights ; and WHEREAS, the Assignor is agreeing to assign patent rights to . NOW, therefore, for the good and valuable remuneration which is received confirms, the said Assignor has sold, transferred, transferred and transferred, and sells, transferred, transferred and identified, to the said assignee, his successors, legal representatives and transfers from the date of entry into force, as stated above, all rights, ownership and interests, to , including in particular the right to require that patent rights be fully and completely the same what would have been transferred and used by the assignor if that transfer and sale had not been carried ou
